Recent Patents on CNS Drug Discovery

Vincenzo Di Marzo
Istituto di Chimica Biomolecolare (I.C.B.)
Consiglio Nazionale delle Ricerche (C.N.R.)
Via Campi Flegrei 34
Pozzuoli, Napoli 80078


Zolpidem Therapy for Movement Disorders

Author(s): Kazuo Abe

Affiliation: Konan Women's University, Department of Nursing and Rehabilitation, 6-2-23 Morikita-cho, Higashinada-Ku, Kobe 658-0001, Japan.

Keywords: Zolpidem, movement disorders, gamma-aminobutyric acid (GABA), Parkinson's disease, progressive supranuclear palsy (PSP)


Zolpidem is a selective agonist of the benzodiazepine subtype receptor BZ1. The highest density of this receptor is in the output structures of the basal ganglia. The basal ganglia are pathologically involved in many movements disorders. Thus, zolpidem has accumulated attention for a possible drug to treat neurological signs and symptoms in Parkinsonian diseases. In this mini-review, I reviewed effects of zolpidem as movement disorders including Parkinsons disease, progressive supranuclear palsy, dystonia and so on. In addition, I reviewed a possible mechanism of zolpidem for movement disorders.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [55 - 60]
Pages: 6
DOI: 10.2174/157488908783421519